- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abivax SA (2X1)
"Abivax SA stock price live, this page displays EPA ABVX stock exchange data. View the ABVX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abivax SA real time stock price chart below.
What Is the Abivax SA Stock Price Today?
The Abivax SA stock price today is 5.9700.
What Is the Stock Symbol for Abivax SA?
The stock symbol for Abivax SA is ""ABVX.""
What Stock Exchange Does Abivax SA Trade On?
Abivax SA is listed and trades on the Paris stock exchange.
Is Abivax SA a Good Stock to Buy?
Determining whether Abivax SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABVX quote. (ISIN: FR0012333284)"
What Is the Abivax SA Stock Price Today?
The Abivax SA stock price today is 5.9700.
What Is the Stock Symbol for Abivax SA?
The stock symbol for Abivax SA is ""ABVX.""
What Stock Exchange Does Abivax SA Trade On?
Abivax SA is listed and trades on the Paris stock exchange.
Is Abivax SA a Good Stock to Buy?
Determining whether Abivax SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABVX quote. (ISIN: FR0012333284)"
5.9700
+0.1400(+2.40%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.9700
5.9700
52 wk Range
4.5750
15.2600
2X1 Scorecard
Full Analysis
Quickly burning through cash
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
5.97005.9700
52 wk Range
4.575015.2600
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2X1 Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
Abivax SA Company Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults and Phase 2b clinical trial of obefazimod in patients with Crohn’s disease. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
Compare 2X1 to Peers and Sector
Metrics to compare | 2X1 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2X1PeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.0x | −0.5x | |
PEG Ratio | −0.12 | −0.01 | 0.00 | |
Price/Book | 9.5x | 1.4x | 2.6x | |
Price / LTM Sales | 35.7x | 9.4x | 2.9x | |
Upside (Analyst Target) | - | 167.9% | 60.5% | |
Fair Value Upside | Unlock | −1.5% | 8.5% | Unlock |
Earnings
Latest Release
Mar 24, 2025
EPS / Forecast
-0.735 / -0.6815
Revenue / Forecast
4.40M / 3.41M
People Also Watch
FAQ
What Is the Abivax SA (2X1) Stock Price Today?
The Abivax SA stock price today is 5.97
What Stock Exchange Does Abivax SA Trade On?
Abivax SA is listed and trades on the Frankfurt Stock Exchange stock exchange.
What Is the Stock Symbol for Abivax SA?
The stock symbol for Abivax SA is "2X1."
What Is the Abivax SA Market Cap?
As of today, Abivax SA market cap is 385.52M.
What is Abivax SA Earnings Per Share?
The Abivax SA EPS is -2.80.
What Is the Next Abivax SA Earnings Date?
Abivax SA will release its next earnings report on Jun 01, 2025.
From a Technical Analysis Perspective, Is 2X1 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.